Vulnerability of Vascular Endothelium in Lipopolysaccharide Toxicity: Effect of (acyl) Carnitine on Endothelial Stability

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 1993 Jan 1

PMID 18475564

Authors

W C Hulsmann

Affiliations

Soon will be listed here.

Abstract

The literature presented illustrates that lipopolysaccharide (LPS), from bacterial cell walls, induces tumour necrosis factor (TNF) synthesis in macrophages. TNF affects a number of cell types, amongst which are endothelial cells, within a few hours. Its injection has been shown to produce all symptoms of the toxic syndrome. In the present communication the vulnerability of endothelial cells will be stressed. These cells require carnitine not only for fatty acid oxidation but also for membrane protection and repair. As endothelial cells lose carnitine during hypoperfusion, it is speculated that the supply of carnitine during the early phase of LPS toxicity in rats might delay or avoid loss of endothelial functions. Earlier it was observed that hearts from rats, injected 3 h previously with LPS, showed strongly increased interstitial fluid production compared to hearts from control rats, even when TNF was present during a 3 h in vitro perfusion. It showed that LPS in vivo generates factors other than TNF, such as platelet activating factor (PAF), that are responsible for the increased capillary permeability.

References

Hulsmann W, Lamers J, Stam H, Breeman W . Calcium overload in endotoxemia. Life Sci. 1981; 29(10):1009-14. DOI: 10.1016/0024-3205(81)90459-8. View

Moncada S, Gryglewski R, Bunting S, Vane J . An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976; 263(5579):663-5. DOI: 10.1038/263663a0. View

Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P . Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987; 84(15):5277-81. PMC: 298838. DOI: 10.1073/pnas.84.15.5277. View

Romano M, Molino M, Cerletti C . Endotoxic lipid A induces intracellular Ca2+ increase in human platelets. Biochem J. 1991; 278 ( Pt 1):75-80. PMC: 1151451. DOI: 10.1042/bj2780075. View

Waage A, Halstensen A, Espevik T . Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987; 1(8529):355-7. DOI: 10.1016/s0140-6736(87)91728-4. View

Hulsmann W, Dubelaar M, de Wit L, Persoon N . Cardiac lipoprotein lipase: effects of lipopolysaccharide and tumor necrosis factor. Mol Cell Biochem. 1988; 79(2):137-45. DOI: 10.1007/BF02424556. View

Hulsmann W, Dubelaar M . Early damage of vascular endothelium during cardiac ischaemia. Cardiovasc Res. 1987; 21(9):674-7. DOI: 10.1093/cvr/21.9.674. View

Glauser M, Zanetti G, Baumgartner J, Cohen J . Septic shock: pathogenesis. Lancet. 1991; 338(8769):732-6. DOI: 10.1016/0140-6736(91)91452-z. View

Beutler B, Greenwald D, Hulmes J, Chang M, Pan Y, Mathison J . Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985; 316(6028):552-4. DOI: 10.1038/316552a0. View

10.

Shukla S . Platelet-activating factor receptor and signal transduction mechanisms. FASEB J. 1992; 6(6):2296-301. DOI: 10.1096/fasebj.6.6.1312046. View

11.

van Hinsbergh V, Scheffer M . Effect of propionyl-L-carnitine on human endothelial cells. Cardiovasc Drugs Ther. 1991; 5 Suppl 1:97-105. DOI: 10.1007/BF00128248. View

12.

Prescott S, Zimmerman G, McIntyre T . Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci U S A. 1984; 81(11):3534-8. PMC: 345543. DOI: 10.1073/pnas.81.11.3534. View

13.

Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A . Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med. 1985; 161(5):984-95. PMC: 2187615. DOI: 10.1084/jem.161.5.984. View

14.

Ward P . Mechanisms of endothelial cell injury. J Lab Clin Med. 1991; 118(5):421-6. View

15.

Bevilacqua M, Pober J, Majeau G, Fiers W, COTRAN R, Gimbrone Jr M . Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A. 1986; 83(12):4533-7. PMC: 323768. DOI: 10.1073/pnas.83.12.4533. View

16.

Anggard E . The endothelium--the body's largest endocrine gland?. J Endocrinol. 1990; 127(3):371-5. DOI: 10.1677/joe.0.1270371. View

17.

Hulsmann W, Dubelaar M . Aspects of fatty acid metabolism in vascular endothelial cells. Biochimie. 1988; 70(5):681-6. DOI: 10.1016/0300-9084(88)90253-2. View

18.

Langeler E, Fiers W, van Hinsbergh V . Effects of tumor necrosis factor on prostacyclin production and the barrier function of human endothelial cell monolayers. Arterioscler Thromb. 1991; 11(4):872-81. DOI: 10.1161/01.atv.11.4.872. View

19.

Hulsmann W, Dubelaar M . Carnitine requirement of vascular endothelial and smooth muscle cells in imminent ischemia. Mol Cell Biochem. 1992; 116(1-2):125-9. DOI: 10.1007/BF01270579. View

20.

Pennica D, Nedwin G, Hayflick J, Seeburg P, Derynck R, Palladino M . Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984; 312(5996):724-9. DOI: 10.1038/312724a0. View